For older patients with acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (HCT) provides the best chance of long-term survival. A formal comparison between matched sibling (SIB), unrelated donor (URD), or umbilical cord blood (UCB) transplantation has not yet been reported in this setting. We compared reduced-intensity conditioning HCT in 197 consecutive patients 50 years and older with AML in complete remission from SIB (n ¼ 82), URD (n ¼ 35), or UCB (n ¼ 80) transplantation. The 3-year cumulative incidences of transplantation-related mortality were 18%, 14%, and 24% with SIB, URD, and UCB transplantation, respectively (P ¼ .22). The 3-year leukemia-free survival rates were 48%, 57%, and 33% with SIB, URD, and UCB transplantation, respectively (P ¼ .009). In multivariate analysis, poor-risk cytogenetics was associated with relapse (hazard ratio, 1.7 [95% confidence interval, 1.0 to 3.0]; P ¼ .04) and worse leukemiafree survival (hazard ratio, 1.6 [95% confidence interval, 1.0 to 2.5]; P ¼ .03), whereas donor choice had no significant impact on overall survival (P ¼ .73). Adjusted 3-year overall survival rates were 55% with SIB, 45% with URD, and 43% with UCB transplantation (P ¼ .26). Until prospective studies are completed, this study supports the recommendation to consider SIB donor, URD, or UCB for HCT for older patients with AML in complete remission. Ó
INTRODUCTION
Acute myeloid leukemia (AML) occurs frequently in older patients, with an overall poor prognosis [1] . Despite the potential benefit of intensified postremission treatments developed in younger adult AML protocols, this does not benefit the older population [2] . For the older AML patient, allogeneic hematopoietic cell transplantation (HCT) likely provides the best chance of long-term survival [3, 4] . HCT is uncommonly used in this population, however, because of the perceived higher risks of transplantation complications, especially using unrelated donors (URDs) or umbilical cord blood (UCB) donors [5] . A large analysis reported comparable outcomes of HCT using reduced-intensity conditioning (RIC) regimens using related donors or URDs among older patients with AML and myelodysplastic syndrome, indicating that age per se is not a contraindication to HCT [6] .
Because older patients less often have available healthy HLA identical matched sibling (SIB) donors, alternative donors may broaden access to HCT. Unrelated umbilical cord blood (UCB) has been increasingly accepted as an alternative donor source for patients without an available SIB or URD [7] [8] [9] [10] . The feasibility of UCB HCT for older patients with AML or myelodysplastic syndrome has been suggested [11] [12] [13] , yet a formal comparison of these 3 graft options for older patients with AML has not been reported. We present comparative outcomes of reduced-intensity conditioning (RIC) HCT for AML patients over age 50 years in complete remission (CR) using SIB donors, URDs, or UCB donors.
METHODS

Study Population
From January 2000 to December 2010, 197 consecutive patients with AML in complete remission age 50 years or more (median age, 59; range, 50 to 74) received RIC and allogeneic HCT in 3 institutions (University of Minnesota, Hospital Saint Louis Paris, and University Hospital of Nantes) either from SIB donors (n ¼ 82), URDs (n ¼ 35), or UCB (n ¼ 80). Disease risks were defined as favorable, intermediate, or poor for AML [14] . Karnofsky performance status was recorded before HCT. All patients were treated on protocols approved by the institutional review board of each hospital. Informed consent was obtained in accordance with the Declaration of Helsinki.
Data were collected prospectively, as Hospital Saint Louis Paris and University Hospital of Nantes belong to the European Group for Blood and Marrow Transplantation (EBMT) and sharing ProMISe (Project Manager Internet Server), which is the central data management system used by the EBMT. Both centers prospectively enter patient information and retrieve data directly over a secure Internet connection. At the University of Minnesota, data on all patients undergoing transplantation are prospectively collected in the institutional bone marrow transplantation research E-mail address: regis.peffaultdelatour@sls.aphp.fr (R. Peffault de Latour).
database. Data on consecutive eligible patients from all 3 sites were retrieved and merged for this combined analysis.
HLA Typing, Matching, and Donor Selection Policy All related donors were HLA-matched SIBs based on family studies. Histocompatibility testing and selection of URDs are described in detail elsewhere [15] . Recipients and URDs were defined as matched ("8/8") if HLA-A, -C, -B, and -DRB1 were identical at the molecular level. All URDs but 1 (7/8) were 8/8 allele matched. SIBs and URDs all received filgrastimmobilized peripheral blood grafts. UCB units were required to be matched at greater than 4 of 6 HLA antigens based on antigen-level HLA-A and -B typing and allele-level HLA-DRB1 typing. Matching at HLA-C, -DQ, and -DP was not considered.
Over the duration of the study, UCB units were required to have a minimum cryopreserved total nucleated cell dose of 2.0 Â 10 7 /kg. The target cell dose was greater than or equal to 3.0 Â 10 7 total nucleated cells/kg, however, resulting in the selection of a second partially HLA-matched UCB unit if available. In those for whom a second UCB unit could be identified, the second unit also had a minimum of 4 of 6 antigens matched with the first unit [10, 16] . Seventy UCB HCT recipients (88%) received 2 UCB units, and 75 (94%) received at least 1 to 2 HLA-mismatched units. In the absence of a matched SIB donor, UCB grafts were the first-choice option for the Minnesota group based on experience and research priorities. In the same irradiation (TBI; 200 cGy on day À1). All patients received prophylaxis for graft-versus-host disease (GVHD) with cyclosporine (from days À3 to þ180), and most also received mycophenolate mofetil (from days À3 to þ30). Hospital Saint-Louis Paris and the University Hospital of Nantes practice the same patient daily care routine as recommended by the Joint Accreditation CommitteeeInternational Society for Cellular Therapy and EBMT, which is similar to the University of Minnesota group. Patients were hospitalized in single rooms ventilated with high-efficiency particulate air filtration systems. Patients received prophylactic low-dose acyclovir until day 100. Documented cytomegalovirus reactivation or infection demonstrated by antigenemia or DNA PCR testing after transplantation was treated with therapeutic doses of ganciclovir or foscarnet (foscavir) (depending on cytopenias and kidney function). Broadspectrum antibiotics were administered for fever during neutropenia, and antifungal coverage was added for persistent fever unresponsive to antibiotic therapy. All patients received fluconazole or voriconazole for prophylaxis of fungal infections for 100 days and trimethoprimsulfamethoxazole for prophylaxis of Pneumocystis juroveci after engraftment for 12 months after transplantation.
Statistical Analysis
The primary endpoint was probability of overall survival (OS). Secondary study endpoints included probability of neutrophil recovery (absolute neutrophil count ! 500/mL for at least 3 days), platelet recovery (platelets !20,000/mL for at least 3 days), leukemia-free survival (LFS), cumulative incidences of acute and chronic GVHD, relapse, and treatmentrelated mortality (TRM). LFS was defined as survival in continuous complete remission (CR). TRM was defined as death after HCT without leukemia relapse. Standard clinical criteria were used to diagnose and grade GVHD [18, 19] .
Time-to-event outcomes were counted from the date of transplantation to the date of event or date of last follow-up. Engraftment and acute GVHD were arbitrarily censored at 100 days, and other outcomes were censored at 36 months, given the study follow-up. Death was considered as a competing risk in analyses of engraftment and acute and chronic GVHD. TRM and relapse were considered to be mutually competing risks. OS and LFS functions were estimated using Kaplan-Meier product-limit estimator. For competing risk analyses, cumulative incidence functions (CIFs) were estimated using the usual methodology [20] .
Characteristics of patients were compared according to donor using Kruskal-Wallis tests, Wilcoxon rank-sum tests, and Fisher' exact tests. Factors associated with outcomes were analyzed using Gray's tests (acute GVHD), proportional hazards models for the cause-specific hazard [21] (relapse and TRM), and Cox proportional hazards models (LFS and OS). Covariates used for adjustment were age (<60 or !60 years), poor cytogenetic risk, disease status at transplantation, interval from diagnosis to HCT (<6 or !6 months for patients that underwent transplantation in CR1), female donor to male recipient, TBI, and ATG. The proportional hazards assumption was checked by examination of Schoenfeld residuals and Grambsch and Therneau's lack-of-fit test [22] . Random center effects were also added to the models and tested using mixed-effects Cox models [23] . All tests were 2-sided, and P .05 was considered as indicating significant association. Analyses were performed using the R statistical software, version 2.15.0 (R Development Core Team, Vienna, Austria).
RESULTS
Patient Characteristics
Patient characteristics were similar between the 3 groups for age, gender, CR stage, and time from diagnosis to HCT (Table 1) . UCB recipients had more frequent high-risk features, including Karnofsky performance score <90% (19% versus 10% SIB and 3% URD; P ¼ .04), female donor to male recipient (44% versus 20% SIB and 17% URD; P ¼ .04), and a trend for more poor risk cytogenetics (UCB 34%, SIB 22%, URD 17%; P ¼ .06). Conditioning regimens also differed between the 3 groups. Fludarabine and low-dose TBI were more frequent in UCB (100% versus 24% in SIB and 11% in URD; P < .0001), fludarabine and busulfan were more frequent in URD (71% versus 43% SIB and 0 UCB, P < .0001), and cyclophosphamide plus low-dose TBI were more frequent in SIB (28% versus 3% URD and 0 UCB, P < .0001). ATG was more frequently used in URD (86% versus 29% SIB and 29% UCB; P < .0001). UCB transplantation was almost exclusively performed at the University of Minnesota, whereas data on URDs were from Hospital Saint Louis Paris and University Hospital of Nantes.
Engraftment and Acute and Chronic GVHD
The to 81%] with UCB; P < .0001) at 3 months. We did not observe graft rejection. Cumulative incidences for acute and chronic GVHD were similar between SIB, URD, and UCB (Table 2) .
TRM, Relapse, LFS, and OS
During follow-up, 94 patients died. The 3-year CIF of TRM was 18% (95% CI, 10 to 28), 14% (95% CI, 5 to 28), and 24% (95% CI, 15 to 34) with SIB, URD, and UCB, respectively (P ¼ .22). The 3-year CIF of relapse was 33% (95% CI, 23 to 44), 29% (95% (Figure 1 ). We found no independent center effect that might have biased our comparison of the 3 sources of stem cells.
DISCUSSION
The aim of this analysis was to study the impact of donor type on survival after HCT in a well-defined cohort of 197 consecutive patients age 50 years or more with AML in CR. In our analysis, adjusted OS and LFS rates were not different between SIB, URD, and UCB HCT. This is important news because a matched SIB donor can only be found for 30% of patients, and many physicians hesitate to refer elderly patients for URD HCT, as shown in a feasibility analysis of RIC regimens for patients older than 50 years with AML [5] .
TRM is classically the main argument not to proceed to HCT from a URD (especially from cord blood) in this older patient population. Engraftment was delayed as previously reported with UCB [10,12], but engraftment incidence was similar to SIB and URD HCT by day 60. Acute and chronic GVHD rates were also similar to 3-year TRM. In a study from the Center for International Blood and Marrow Transplantation Research, TRM was greater using UCB compared with that after URD peripheral blood, but that study included all adult patients with acute leukemias, not just older adults with AML in CR receiving an RIC regimen [24] .
In patients with AML, the other leading cause of treatment failure is relapse [25] [26] [27] . In our study, there was a trend for higher 3-year CIF of relapse with UCB, and the univariate analysis showed a slightly lower 3-year LFS rate after UCB HCT. However, the UCB group had more patients with Karnofsky performance scores <90% and a trend for worse cytogenetic risk. In adjusted multivariate analysis, poor-risk cytogenetics was associated with a significant and nearly double risk of relapse, worse LFS rates, and a trend for worse OS. The higher relapse rate observed with UCB might thus be related to the imbalance in cytogenetic risk between the 3 groups. Notably, we found no significant differences in OS between age subgroups (age 60 þ versus age 50 to 60) or remission status (CR2 or 3 versus CR1). The selection of higher-risk patients (including poor-risk cytogenetics) for alternative donor HCT during CR1 may thus explain, at least in part, the latter finding. Importantly, adjusted 3-year OS was similar using SIB, URD, or UCB HCT. These results should be considered with caution, however, because the conditioning regimen varied somewhat between the centers. Moreover, patients that underwent transplantation with a URD more often received ATG in the conditioning regimen, which could also influence our reported outcomes. The use of TBI-containing conditioning was associated with a nonsignificant, but somewhat worse OS rate in recipients of matched related donor and URD grafts, whereas all patients with UCB grafts received low-dose TBI. Although the association of a higher risk of relapse with lowdose TBI is in accordance with what has already been published [28] , the association with a higher rate of TRM is surprising. We believe this analysis is potentially related to confounding factors (all patients who underwent cord transplantations received TBI 2 Gy, whereas this regimen was used only in half of the patients who received an SIB transplantation). The retrospective setting of our study as well as the current results may suggest that the use of non-TBI regimens for SIB and URD grafts need to reassessed, which is best done in prospective randomized trials.
This study has validity in that we included consecutive and prospective data from 3 experienced centers, each with consistent strategies for donor selection for older AML patients and no SIB donors. At the University of Minnesota, based on experience and research priorities, UCB grafts were the first-choice option, whereas the Hospital Saint Louis Paris and the University Hospital of Nantes preferentially selected URD. Each center used consistent and similar conditioning regimens, GVHD prophylaxis, and supportive care. We also found no independent center effect that might have biased our direct comparison of the 3 sources of stem cells. These consistent and homogeneous treatment strategies provide insights beyond registry studies where heterogeneity might confound some comparisons. We cannot exclude a possible bias due to the almost exclusive use of UCB grafts at the University of Minnesota versus URD at Hospital Saint Louis Paris and the University Hospital of Nantes, however, and that 40% of the patients with UCB underwent transplantation in CR2 to 3. Moreover, our study may be limited by its retrospective nature and the modest number of patients, yielding insufficient power to detect small but clinically important differences in outcomes. In particular, the population of URD transplantation is under-represented. Enrollment bias might result in only patients with no or few comorbidities referred for URD transplantations or only those with the highest risk being referred for transplantation in an early CR. To minimize this bias, we adjusted the statistical analysis for baseline differences in the various patient cohorts. It is desirable to study the impact of donor type in disease-specific prospective clinical trials, and we may expect additional information on the impact of donor type to come from prospective studies being run by the AML study groups.
Overall, these data suggest comparable outcome when using SIB donors, URDs, or UCB donors in patients age 50 years and older with AML in CR. Poor cytogenetic risk was the dominant prognostic factor, influencing relapse and LFS rates with a trend for worse OS rates. Despite the methodological restrictions of a retrospective analysis, our data support the recommendation to consider SIB, URD, or UCB for HCT for older patients with AML in CR. The number of older patients with AML who benefit from a postremission therapy with allogeneic HCT may thereby increase.
ACKNOWLEDGMENTS
Conflict of interest statement: There are no conflicts of interest to report.
Authorship statement: G.S. and D.W. equally contributed and should be considered as senior coauthors. R.P.L., R.P., G.S., and D.W. conceived and designed the study. R.P.L., C.B., P.C., M.R., E.W., A.X., C.U., J.L., N.D., M.M., G.S., and D.W. provided study materials and patients. R.P.L., R.P., G.S., and D.W. collected and assembled the data. R.P.L., R.P., G.S., and D.W. analyzed and interpreted the data. R.P.L., R.P., G.S., and D.W. wrote the manuscript. R.P.L., C.B., R.P., P.C., M.R., E.W., A.X., C.U., J.L., N.D., M.M., G.S., and D.W. had final approval of the manuscript.
Financial disclosure: The authors have nothing to disclose.
